AU2013317791B2 - Inhibitors of beta-hydrolase for treatment of cancer - Google Patents
Inhibitors of beta-hydrolase for treatment of cancer Download PDFInfo
- Publication number
- AU2013317791B2 AU2013317791B2 AU2013317791A AU2013317791A AU2013317791B2 AU 2013317791 B2 AU2013317791 B2 AU 2013317791B2 AU 2013317791 A AU2013317791 A AU 2013317791A AU 2013317791 A AU2013317791 A AU 2013317791A AU 2013317791 B2 AU2013317791 B2 AU 2013317791B2
- Authority
- AU
- Australia
- Prior art keywords
- amino
- furanone
- oxy
- chlorophenyl
- phenylmethylsulfonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 CC(C1=O)(OC(N)=C1O*C=C=I)[Al] Chemical compound CC(C1=O)(OC(N)=C1O*C=C=I)[Al] 0.000 description 3
- JKEOLWUOJVQCNL-UHFFFAOYSA-N Cc1c(NC)[o]c([AlH2])c1C Chemical compound Cc1c(NC)[o]c([AlH2])c1C JKEOLWUOJVQCNL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/66—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261704014P | 2012-09-21 | 2012-09-21 | |
| US61/704,014 | 2012-09-21 | ||
| PCT/US2013/061050 WO2014047519A2 (en) | 2012-09-21 | 2013-09-20 | Inhibitors of beta-hydrolase for treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013317791A1 AU2013317791A1 (en) | 2015-05-07 |
| AU2013317791B2 true AU2013317791B2 (en) | 2018-05-10 |
Family
ID=50342080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013317791A Ceased AU2013317791B2 (en) | 2012-09-21 | 2013-09-20 | Inhibitors of beta-hydrolase for treatment of cancer |
Country Status (10)
| Country | Link |
|---|---|
| US (8) | US9771356B2 (enExample) |
| EP (2) | EP3345596B1 (enExample) |
| JP (1) | JP6469009B2 (enExample) |
| KR (1) | KR102137180B1 (enExample) |
| CN (2) | CN110818660B (enExample) |
| AU (1) | AU2013317791B2 (enExample) |
| CA (1) | CA2885762C (enExample) |
| ES (2) | ES2865412T3 (enExample) |
| HK (1) | HK1208805A1 (enExample) |
| WO (2) | WO2014047447A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110818660B (zh) | 2012-09-21 | 2023-09-12 | 罗得岛医院 | 用于治疗癌症的β-羟化酶抑制剂 |
| WO2019012159A1 (en) * | 2017-07-14 | 2019-01-17 | Protea Biopharma N.V. | METHODS AND MEANS FOR DIAGNOSING AND / OR TREATING A FATIGUE-ASSOCIATED DISEASE |
| US10961320B2 (en) | 2018-06-18 | 2021-03-30 | Midwestern University | Monoclonal antibodies targeting epitopes of ASPH |
| CN109364251A (zh) * | 2018-12-06 | 2019-02-22 | 苏州大学 | Tet蛋白在治疗抑郁症中的应用 |
| EP3923922A4 (en) | 2019-02-15 | 2022-03-30 | Midwestern University | Isotopically-stabilized tetronimide compounds |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE39717C (de) | H. LEHMANN in München, Enhuberstr. 5 part | Bleistifthalter | ||
| DD39717A (enExample) * | ||||
| WO1987000729A1 (en) * | 1985-08-02 | 1987-02-12 | Chevron Research Company | Herbicidal 2-(oxa or thia heterocycle)5-amino-3-oxo-4-(substituted-phenyl)-2,3-dihydrofurans |
| US5314913A (en) * | 1992-12-08 | 1994-05-24 | American Home Products Corporation | 4- or 5-(substituted sulfonyl)methyl-3(2H)-furanones |
| JPH09110853A (ja) * | 1995-10-12 | 1997-04-28 | Kikkoman Corp | ４‐アシルオキシフラノン誘導体又はその塩及びその製造方法 |
| US5698585A (en) * | 1995-04-13 | 1997-12-16 | Kikkoman Corporation | Pharmaceutical preparation for prevention and/or treatment for cataract |
| UA57002C2 (uk) | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування |
| US5877193A (en) * | 1996-07-19 | 1999-03-02 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
| TW528755B (en) * | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
| ATE244232T1 (de) * | 1997-03-14 | 2003-07-15 | Merck Frosst Canada Inc | (methylsulfonyl)phenyl-2-(5h)-furanone mit sauerstoff-bindung als cox-2-hemmer |
| US20030031670A1 (en) | 1999-11-08 | 2003-02-13 | Jack R. Wands | Diagnosis and treatment of malignant neoplasms |
| US6835370B2 (en) | 1999-11-08 | 2004-12-28 | Rhode Island Hospital | Diagnosis and treatment of malignant neoplasms |
| US20050123545A1 (en) | 1999-11-08 | 2005-06-09 | Wands Jack R. | Diagnosis and treatment of malignant neoplasms |
| WO2003018575A1 (en) | 2001-08-24 | 2003-03-06 | Wyeth Holdings Corporation | 5-substituted-3(2h)-furanones useful for inhibition of farnesyl-protein transferase |
| US6667330B2 (en) | 2002-01-31 | 2003-12-23 | Galileo Pharmaceuticals, Inc. | Furanone derivatives |
| AU2002950862A0 (en) * | 2002-08-19 | 2002-09-12 | Biosignal Pty Ltd | Furanone derivatives and methods of making same |
| DE60330587D1 (de) * | 2002-10-16 | 2010-01-28 | Isis Innovation | Screening-Methoden unter Verwendung eines Strukturmodells von FIH |
| WO2005070916A1 (en) * | 2004-01-09 | 2005-08-04 | Eli Lilly And Company | Thiophene and furan compounds |
| EP2227233B1 (en) | 2007-11-30 | 2013-02-13 | Newlink Genetics | Ido inhibitors |
| EP2576532B1 (en) * | 2010-06-07 | 2018-07-18 | Novomedix, LLC | Furanyl compounds and the use thereof |
| CN110818660B (zh) | 2012-09-21 | 2023-09-12 | 罗得岛医院 | 用于治疗癌症的β-羟化酶抑制剂 |
-
2013
- 2013-09-20 CN CN201910949656.0A patent/CN110818660B/zh not_active Expired - Fee Related
- 2013-09-20 WO PCT/US2013/060934 patent/WO2014047447A2/en not_active Ceased
- 2013-09-20 ES ES17202827T patent/ES2865412T3/es active Active
- 2013-09-20 CN CN201380061004.4A patent/CN104902889A/zh active Pending
- 2013-09-20 EP EP17202827.6A patent/EP3345596B1/en not_active Not-in-force
- 2013-09-20 US US14/430,101 patent/US9771356B2/en active Active
- 2013-09-20 HK HK15109523.0A patent/HK1208805A1/xx unknown
- 2013-09-20 CA CA2885762A patent/CA2885762C/en active Active
- 2013-09-20 WO PCT/US2013/061050 patent/WO2014047519A2/en not_active Ceased
- 2013-09-20 ES ES13838498.7T patent/ES2660822T3/es active Active
- 2013-09-20 AU AU2013317791A patent/AU2013317791B2/en not_active Ceased
- 2013-09-20 EP EP13838498.7A patent/EP2897607B1/en not_active Not-in-force
- 2013-09-20 KR KR1020157010188A patent/KR102137180B1/ko not_active Expired - Fee Related
- 2013-09-20 JP JP2015533237A patent/JP6469009B2/ja not_active Expired - Fee Related
-
2017
- 2017-07-17 US US15/651,842 patent/US10106532B2/en active Active
- 2017-09-26 US US15/715,989 patent/US10710995B2/en active Active
-
2018
- 2018-09-14 US US16/131,275 patent/US10351555B2/en active Active
-
2019
- 2019-06-12 US US16/439,253 patent/US10787445B2/en active Active
-
2020
- 2020-06-02 US US16/890,680 patent/US20200361925A1/en not_active Abandoned
- 2020-09-23 US US17/029,127 patent/US20210032233A1/en not_active Abandoned
-
2022
- 2022-04-14 US US17/720,472 patent/US20220251076A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220251076A1 (en) | Inhibitors of Beta-Hydoxylase for Treatment of Cancer | |
| CN102015606A (zh) | IRE-1α抑制剂 | |
| US10961211B2 (en) | Isotopically-stabilized tetronimide compounds | |
| US20210052561A1 (en) | Targeting aspartate beta-hydroxylase suppresses tumor malignancy and metastasis | |
| US12180188B2 (en) | Antifibrotic compounds and related methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |